Analysis of the risk factors of radiation pneumonitis and the predictive ability of dosiomics in non-small-cell lung cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Analysis of the risk factors of radiation pneumonitis and the predictive ability of dosiomics in non-small-cell lung cancer
Authors
Keywords
-
Journal
Future Oncology
Volume 19, Issue 32, Pages 2157-2169
Publisher
Future Medicine Ltd
Online
2023-10-27
DOI
10.2217/fon-2023-0316
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systemic and Radiation Therapy Approaches for Locally Advanced Non–Small-Cell Lung Cancer
- (2022) Kristin A. Higgins et al. JOURNAL OF CLINICAL ONCOLOGY
- Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors
- (2022) Jianping Bi et al. Frontiers in Immunology
- Review of Radiomics- and Dosiomics-based Predicting Models for Rectal Cancer
- (2022) Yun Qin et al. Frontiers in Oncology
- Evaluation of DIR algorithm performance in real patients for radiotherapy treatments: A systematic review of operator-dependent strategies
- (2022) C. Dossun et al. Physica Medica-European Journal of Medical Physics
- Safety and efficacy of combination therapy using programmed cell death protein‐1/programmed cell death ligand‐1 inhibitors and radiotherapy in patients with non‐small‐cell lung cancer: A systematic review and meta‐analysis
- (2021) Yichao Geng et al. Cancer Medicine
- Radiomics and Dosiomics for Predicting Local Control after Carbon-Ion Radiotherapy in Skull-Base Chordoma
- (2021) Giulia Buizza et al. Cancers
- Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non–Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab
- (2021) Takashi Shintani et al. Clinical Lung Cancer
- A Phase I Trial of Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study)
- (2021) Christine M. Bestvina et al. Journal of Thoracic Oncology
- Dosiomics-based prediction of radiation-induced hypothyroidism in nasopharyngeal carcinoma patients
- (2021) Wenting Ren et al. Physica Medica-European Journal of Medical Physics
- On dose cube pixel spacing pre-processing for features extraction stability in dosiomic studies
- (2021) L. Placidi et al. Physica Medica-European Journal of Medical Physics
- Multi-view radiomics and dosiomics analysis with machine learning for predicting acute-phase weight loss in lung cancer patients treated with radiotherapy
- (2020) Sang Ho Lee et al. PHYSICS IN MEDICINE AND BIOLOGY
- Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy
- (2019) Mengqian Li et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Prediction of response after chemoradiation for esophageal cancer using a combination of dosimetry and CT radiomics
- (2019) Xiance Jin et al. EUROPEAN RADIOLOGY
- Dosiomics: Extracting 3D Spatial Features From Dose Distribution to Predict Incidence of Radiation Pneumonitis
- (2019) Bin Liang et al. Frontiers in Oncology
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- Prior or concurrent radiotherapy and nivolumab immunotherapy in non–small cell lung cancer
- (2019) Gishan Ratnayake et al. Asia-Pacific Journal of Clinical Oncology
- Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients
- (2018) Francesco Fiorica et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Texture analysis of 3D dose distributions for predictive modelling of toxicity rates in radiotherapy
- (2018) Linda Rossi et al. RADIOTHERAPY AND ONCOLOGY
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Radiotherapy and immunotherapy: a beneficial liaison?
- (2017) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis
- (2013) David A. Palma et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started